

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

ASTRAZENECA LP, ASTRAZENECA
AB, ASTRAZENECA UK LIMITED, and
ASTRAZENECA PHARMACEUTICALS LP,

Plaintiffs,

v.

SIGMAPHARM LABORATORIES
LLC ET AL.,

Defendant.

Civil Action No. 15-cv-01000-RGA
CONSOLIDATED

ASTRAZENECA LP, ASTRAZENECA
AB, ASTRAZENECA UK LIMITED, and
ASTRAZENECA PHARMACEUTICALS LP,

Plaintiffs,

v.

WATSON LABORATORIES, INC.,

Defendant.

Civil Action No. 16-cv-0338-RGA
Civil Action No. 15-cv-01002-RGA

CONSENT JUDGMENT

AstraZeneca LP, AstraZeneca AB, AstraZeneca UK Limited, and AstraZeneca Pharmaceuticals LP (hereinafter collectively "AstraZeneca"), and Watson Laboratories, Inc. (hereinafter "Defendant"), the parties in the above-captioned action ("the Action"), have agreed to terms and conditions representing a negotiated settlement of this Action and have set forth those terms and conditions in a Settlement Agreement (the "Settlement Agreement"). Now the parties, by their respective undersigned attorneys, hereby stipulate and consent to entry of judgment and an injunction in this Action as follows:

IT IS this 14th day of March, 2018:

ORDERED, ADJUDGED AND DECREED as follows:


1. This District Court has jurisdiction over the subject matter of the above Action and has personal jurisdiction over the parties.
2. As used in this Consent Judgment, (i) the term “Defendant Product” shall mean a drug product sold, offered for sale or distributed pursuant to Abbreviated New Drug Application No. 208390 (and defined in greater detail in the Settlement Agreement); and (ii) the term “Affiliate” shall mean any entity or person that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with Defendant; for purposes of this definition, “control” means (a) ownership, directly or through one or more intermediaries, of (1) more than fifty percent (50%) of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or (2) more than fifty percent (50%) of the equity interests in the case of any other type of legal entity or status as a general partner in any partnership, or (b) any other arrangement whereby an entity or person has the right to elect a majority of the Board of Directors or equivalent governing body of a corporation or other entity or the right to direct the management and policies of a corporation or other entity.
3. Unless otherwise specifically authorized pursuant to the Settlement Agreement, Defendant, and any anyone acting on behalf of Defendant, including any of its Affiliates, successors and assigns, is enjoined from infringing the Licensed Patents by making, having made, using, selling, offering to sell, importing or distributing of the Defendant Product.

4. Compliance with this Consent Judgment may be enforced by AstraZeneca and its successors in interest, or assigns, as permitted by the terms of the Settlement Agreement.

5. This District Court retains jurisdiction to enforce or supervise performance under this Consent Judgment and the Settlement Agreement.

6. All claims, counterclaims, affirmative defenses and demands in this action are hereby dismissed with prejudice and without costs, disbursements or attorneys' fees to any party.

7. This Stipulated Consent Judgment and Injunction does not impact the U.S. Food and Drug Administration's ability to grant final approval of the Defendant Product.


The Honorable Richard D. Andrews
United States District Judge